Rxivist logo

Early induction of SARS-CoV-2 specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients

By Anthony T Tan, Martin Linster, Chee Wah Tan, Nina Le Bert, Wan Ni Chia, Kamini Kunasegaran, Yan Zhuang, Christine Y. L. Tham, Adeline Chia, Gavin J. Smith, Barnaby Young, Shirin Kalimuddin, Jenny G. H. Low, David Lye, Lin-Fa Wang, Antonio Bertoletti

Posted 16 Oct 2020
bioRxiv DOI: 10.1101/2020.10.15.341958

Virus-specific humoral and cellular immunity act synergistically to protect the host from viral infection. We interrogated the dynamic changes of virological and immunological parameters in 12 patients with symptomatic acute SARS-CoV-2 infection from disease onset to convalescence or death. We quantified SARS-CoV-2 viral RNA in the respiratory tract in parallel with antibodies and circulating T cells specific for various structural (NP, M, ORF3a and spike) and non-structural proteins (ORF7/8, NSP7 and NSP13). We observed that while rapid induction and quantity of humoral responses were associated with increased disease severity, an early induction of SARS-CoV-2 specific T cells was present in patients with mild disease and accelerated viral clearance. These findings provide further support for a protective role of SARS-CoV-2 specific T cells over antibodies during SARS-CoV-2 infection with important implications in vaccine design and immune-monitoring. ### Competing Interest Statement A.B. is a cofounder and A.T.T. consults for Lion TCR, a biotech company developing T cell receptors for treatment of virus-related diseases and cancers. None of the other authors has any competing interest related to the study.

Download data

  • Downloaded 1,085 times
  • Download rankings, all-time:
    • Site-wide: 16,577
    • In immunology: 438
  • Year to date:
    • Site-wide: 4,689
  • Since beginning of last month:
    • Site-wide: 7,309

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide


Sign up for the Rxivist weekly newsletter! (Click here for more details.)